Publicaciones en colaboración con investigadores/as de Harvard Medical School (34)

2024

  1. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative)

    Future oncology (London, England), Vol. 20, Núm. 11, pp. 635-651

  2. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

2023

  1. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  2. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659

  3. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer

    European Journal of Cancer, Vol. 178, pp. 23-33

  4. Impact of Long-Term Evoked Compound Action Potential Controlled Closed-Loop Spinal Cord Stimulation on Sleep Quality in Patients With Chronic Pain: An EVOKE Randomized Controlled Trial Study Subanalysis

    Neuromodulation, Vol. 26, Núm. 5, pp. 1030-1038

  5. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

  6. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2998-3008

  7. Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997

  8. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

2022

  1. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 14

  2. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139

  3. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    CA Cancer Journal for Clinicians, Vol. 72, Núm. 2, pp. 165-182

  4. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  5. Immunotherapy for early triple negative breast cancer: research agenda for the next decade

    npj Breast Cancer, Vol. 8, Núm. 1

  6. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 29, pp. 3365-3376

  7. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis

    npj Breast Cancer, Vol. 8, Núm. 1

  8. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

    npj Breast Cancer, Vol. 8, Núm. 1

  9. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations

    JAMA Oncology, Vol. 8, Núm. 11, pp. 1668-1675

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027